Quell Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
150
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$24.7M
- Investors
-
17
Quell Therapeutics General Information
Description
Developer of engineered regulatory cell therapies designed for immune-mediated diseases. The company's therapies feature a multi-modular engineering approach, phenotype-lock technology, scalable manufacturing, and targeted tissue engraftment, enabling biotechnology and clinical research markets to pursue durable immune-tolerance therapies in transplantation and autoimmune conditions.
Contact Information
Website
www.quell-tx.comCorporate Office
- 3rd Floor, Translation & Innovation Hub
- 84 Wood Lane
- London W12 0BZ
- England, United Kingdom
Corporate Office
- 3rd Floor, Translation & Innovation Hub
- 84 Wood Lane
- London W12 0BZ
- England, United Kingdom
Quell Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC (Series A) | 09-Jun-2023 | $24.7M | Completed | Clinical Trials - Phase 2 | ||
| 4. Secondary Transaction - Private | Completed | Clinical Trials - Phase 2 | ||||
| 3. Early Stage VC (Series B) | 24-Nov-2021 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC | 12-Feb-2021 | $83.5M | $83.5M | Completed | Clinical Trials - Phase 2 | |
| 1. University Spin-Out | 19-Mar-2019 | Completed | Startup |
Quell Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B Preferred | ||||||||
| Series B Preferred | ||||||||
| Series A Preferred | 46,500,000 | $0.000012 | $1.24 | $1.24 | 1x | $1.24 | 33.08% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Quell Therapeutics Comparisons
Industry
Financing
Details
Quell Therapeutics Competitors (24)
One of Quell Therapeutics’s 24 competitors is TRexBio, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TRexBio | Formerly VC-backed | South San Francisco, CA | ||||
| Annexon Biosciences | Formerly VC-backed | Brisbane, CA | ||||
| GentiBio | Venture Capital-Backed | Cambridge, MA | ||||
| Kyverna | Formerly VC-backed | Emeryville, CA | ||||
| Senti Biosciences Holdings | Formerly VC-backed | South San Francisco, CA |
Quell Therapeutics Patents
Quell Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202509847-D0 | Chimeric antigen receptor | Pending | 20-Jun-2025 | ||
| GB-202509833-D0 | Expression construct | Pending | 20-Jun-2025 | ||
| GB-202509839-D0 | Expression construct | Pending | 20-Jun-2025 | ||
| GB-202509842-D0 | Expression construct | Pending | 20-Jun-2025 | ||
| GB-202509829-D0 | Nucleic acid molecules | Pending | 20-Jun-2025 | A61K40/418 |
Quell Therapeutics Signals
Quell Therapeutics Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AstraZeneca | Corporation | Minority | ||
| Revelation Partners | Venture Capital | Minority | ||
| Breakthrough Energy | Impact Investing | Minority | ||
| British Business Bank | Lender/Debt Provider | Minority | ||
| Fidelity Management & Research Company | Asset Manager | Minority |
Quell Therapeutics FAQs
-
When was Quell Therapeutics founded?
Quell Therapeutics was founded in 2019.
-
Where is Quell Therapeutics headquartered?
Quell Therapeutics is headquartered in London, United Kingdom.
-
What is the size of Quell Therapeutics?
Quell Therapeutics has 150 total employees.
-
What industry is Quell Therapeutics in?
Quell Therapeutics’s primary industry is Drug Discovery.
-
Is Quell Therapeutics a private or public company?
Quell Therapeutics is a Private company.
-
What is the current valuation of Quell Therapeutics?
The current valuation of Quell Therapeutics is .
-
What is Quell Therapeutics’s current revenue?
The current revenue for Quell Therapeutics is .
-
How much funding has Quell Therapeutics raised over time?
Quell Therapeutics has raised $264M.
-
Who are Quell Therapeutics’s investors?
AstraZeneca, Revelation Partners, Breakthrough Energy, British Business Bank, and Fidelity Management & Research Company are 5 of 17 investors who have invested in Quell Therapeutics.
-
Who are Quell Therapeutics’s competitors?
TRexBio, Annexon Biosciences, GentiBio, Kyverna, and Senti Biosciences Holdings are some of the 24 competitors of Quell Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process